, a specialty pharmaceutical company, reported financial results because of its third quarter ended September 30 today, 2011 and highlighted its recent corporate progress.0 million private placement of common warrants and stock. In July 2011, the business commenced a thorough QT study made to support the brand new Drug Software resubmission for APF530. The scholarly study will examine the result of APF530 on the QT interval in healthy volunteers. The ongoing company expects to report results from this study in the first quarter of 2012.In addition, two deaths occurred beyond your scholarly studies. A 9-year-old girl died from disease progression around three months after trial discontinuation due to an unsatisfactory therapeutic impact. A 19-year-old woman died more than 2 years after receiving the last dosage of canakinumab in the stage 2 trial18; the patient’s cerebrospinal-fluid and blood cultures were positive for Streptococcus pneumoniae. Discussion We conducted two parallel studies to measure the efficacy and security of canakinumab in the treating systemic JIA with dynamic systemic features.